IMITREX STATDOSE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for IMITREX STATDOSE (IMITREX STATDOSE).

How it works

Selective agonist at serotonin 5-HT1B/1D receptors, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission.

What the body does with it

Metabolism	Primarily metabolized by monoamine oxidase (MAO); CYP450 enzymes play a minor role.
Excretion	Approximately 60% renal, 40% fecal (via bile); <1% unchanged in urine.
Half-life	Terminal half-life ~2 hours; clinical context: no significant accumulation with repeated dosing.
Protein binding	14-21%; primarily to albumin.
Volume of Distribution	2.4 L/kg; indicates extensive tissue distribution.
Bioavailability	Subcutaneous injection: 97%; oral tablet: 15% (first-pass metabolism).
Onset of Action	Subcutaneous injection: 10-20 minutes; oral tablet: 30-60 minutes.
Duration of Action	Subcutaneous injection: 2-4 hours; oral tablet: 4-6 hours; clinical notes: may require repeat dosing after 2 hours if symptoms recur.

Classification & Brands

Dosing & administration

6 mg subcutaneously once, may repeat after 1 hour if needed; maximum 12 mg in 24 hours.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment; use caution.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh A and B, use with caution; no specific dose adjustment guidelines available.
Pediatric use	Safety and effectiveness not established in pediatric patients; not recommended for use in children.
Geriatric use	Use with caution due to increased risk of adverse events (e.g., coronary artery disease). Start at lowest effective dose; no specific dose adjustment recommended.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for IMITREX STATDOSE (IMITREX STATDOSE).

Breastfeeding	Sumatriptan is excreted in breast milk in small amounts, with an M/P ratio of approximately 5:1 (milk:plasma). Relative infant dose is 3-6% of maternal weight-adjusted dose. No adverse effects reported in infants. Consider benefit of breastfeeding vs. risk of drug exposure. Alternative medications with lower transfer may be preferred.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: no increased risk of major congenital anomalies in human studies, but animal studies show embryolethality and fetal abnormalities. Second and third trimesters: associated with decreased uterine blood flow and potential fetal hypoxia; use only if benefit outweighs risk. No evidence of teratogenicity in humans, but limited data.

Warnings & precautions

■ FDA Black Box Warning

Not recommended for use in patients with risk factors for CAD unless a cardiovascular evaluation provides evidence that the patient is free of CAD.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Ischemic heart disease","Prior myocardial infarction","Coronary artery vasospasm including Prinzmetal's angina","Uncontrolled hypertension","Basilar or hemiplegic migraine","Concurrent use or within 24 hours of ergotamine derivatives or another 5-HT1 agonist","Severe hepatic impairment","Hypersensitivity to sumatriptan or any component"]

Clinical Precautions

Precautions

["Risk of myocardial ischemia/infarction and other cardiac events","Cerebral/subarachnoid hemorrhage","Coronary artery vasospasm","Transient/permanent blindness","Serotonin syndrome (especially with SSRIs/SNRIs)","Medication overuse headache","Ischemic bowel disease"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

IMITREX STATDOSE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for IMITREX STATDOSE (IMITREX STATDOSE).

How it works

Selective agonist at serotonin 5-HT1B/1D receptors, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission.

What the body does with it

Metabolism	Primarily metabolized by monoamine oxidase (MAO); CYP450 enzymes play a minor role.
Excretion	Approximately 60% renal, 40% fecal (via bile); <1% unchanged in urine.
Half-life	Terminal half-life ~2 hours; clinical context: no significant accumulation with repeated dosing.
Protein binding	14-21%; primarily to albumin.
Volume of Distribution	2.4 L/kg; indicates extensive tissue distribution.
Bioavailability	Subcutaneous injection: 97%; oral tablet: 15% (first-pass metabolism).
Onset of Action	Subcutaneous injection: 10-20 minutes; oral tablet: 30-60 minutes.
Duration of Action	Subcutaneous injection: 2-4 hours; oral tablet: 4-6 hours; clinical notes: may require repeat dosing after 2 hours if symptoms recur.

Classification & Brands

Dosing & administration

6 mg subcutaneously once, may repeat after 1 hour if needed; maximum 12 mg in 24 hours.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment; use caution.
Liver impairment	Contraindicated in severe hepatic impairment (Child-Pugh C). For Child-Pugh A and B, use with caution; no specific dose adjustment guidelines available.
Pediatric use	Safety and effectiveness not established in pediatric patients; not recommended for use in children.
Geriatric use	Use with caution due to increased risk of adverse events (e.g., coronary artery disease). Start at lowest effective dose; no specific dose adjustment recommended.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for IMITREX STATDOSE (IMITREX STATDOSE).

Breastfeeding	Sumatriptan is excreted in breast milk in small amounts, with an M/P ratio of approximately 5:1 (milk:plasma). Relative infant dose is 3-6% of maternal weight-adjusted dose. No adverse effects reported in infants. Consider benefit of breastfeeding vs. risk of drug exposure. Alternative medications with lower transfer may be preferred.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: no increased risk of major congenital anomalies in human studies, but animal studies show embryolethality and fetal abnormalities. Second and third trimesters: associated with decreased uterine blood flow and potential fetal hypoxia; use only if benefit outweighs risk. No evidence of teratogenicity in humans, but limited data.

Warnings & precautions

■ FDA Black Box Warning

Not recommended for use in patients with risk factors for CAD unless a cardiovascular evaluation provides evidence that the patient is free of CAD.